B+
Bull case
0%
Probability
Target price
$25.50
-1.3% vs current
MD
Pediatrix Medical GroupBNYSE / Health Care Equipment & Services
Last Price
At close
2026-07-22
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
0%
Probability
Target price
$22.00
-14.8% vs current
B-
Bear case
0%
Probability
Target price
$18.00
-30.3% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+32.1
Score
AI commentary
T+3 sentiment is mildly constructive but still restrained. Company-source evidence confirmed a Q1 beat and guidance reaffirmation, AP and Zacks framed the print as ahead of expectations, and the stock was $22.93 on May 7 versus about $23.23 intraday on May 8, which points to a modest positive reaction rather than a broad rerating. Checked sources did not surface a clear post-print target-reset cycle, so this remains a monitoring-style positive view, not a high-conviction breakout call.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07eventAnnual-meeting incentive-plan expansion adds a mild dilution overhangMedium impact
On May 7 shareholders approved an amended incentive compensation plan that increased shares available for issuance by 8,000,000; this is not a thesis-breaker, but it can temper multiple expansion after a modest earnings beat [#8-K-2026-05-07].
2026-05-20catalystQ1 beat with full-year EBITDA outlook reaffirmedMedium impact
The May 5 earnings release showed Q1 net revenue of $476.2 million, adjusted EPS of $0.44, adjusted EBITDA of $58.2 million, and a reaffirmed 2026 adjusted EBITDA outlook of $280 million to $300 million; that keeps the post-print setup constructive, but much of the beat was already tied to reimbursement and mix rather than volume acceleration [#8-K-2026-05-05].
2026-12-31catalystReimbursement, acuity, and hospital-fee gains must keep offsetting softer volumesHigh impact
Q1 same-unit revenue rose 2.8%, driven by 4.4% growth from reimbursement-related factors, hospital contract administrative fees, higher neonatology acuity, and slightly better payor mix, while patient-service volume was down 1.6%; if that mix-driven improvement holds, the earnings base can stay firm, but the model is still relying on pricing/mix more than traffic [#10-Q-2026-05-05][#8-K-2026-05-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology